Saturday 17 October 2026 Export LYEL’s income statement to Excel — free account

Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36,000.00, down 41.0% from fiscal 2024. In the quarter to June 2026, revenue fell 50.0%, EPS grew 33.6% and free cash flow grew 1.31%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

8.12 0.07 −0.85%

Follow LYEL

Alert me

Market cap: $200.7M
P/E: 0.0×
Fwd P/E: −1.6×
Dividend yield: —
F-score: 2/9
Altman Z: −5.10
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

	Older periods	Sep '25	Dec '25	Mar '26	Jun '26
P/E ratio Full definition →	+8 more quarters Free account	0.00	0.00	0.00	0.00
P/S ratio Full definition →		7,235.91	14,614.52	14,155.89	12,157.93
P/FCF ratio Full definition →		0.00	0.00	0.00	0.00
P/Operating CF Full definition →		(10.38)	(16.31)	(11.40)	(9.68)
P/B ratio Full definition →		0.90	2.12	1.60	1.40
Price to Tangible BV Full definition →		0.90	2.12	1.60	1.40
EV/Sales Full definition →		(559.80)	7,747.29	5,961.60	4,598.60
EV/EBITDA Full definition →		0.07	0.00	0.00	0.00
EV/Operating CF Full definition →		0.14	(1.86)	(1.38)	(0.93)
EV/FCF Full definition →		0.12	(1.45)	(1.05)	(0.71)
Quick Ratio Full definition →		10.03	5.00	6.88	5.12
Current Ratio Full definition →		10.30	5.28	7.23	5.36
Net Debt/EBITDA Full definition →		8.95	1.96	5.93	4.44
Debt/Assets Full definition →		0.00%	0.00%	0.00%	0.00%
Debt/Equity Full definition →		0.00	0.00	0.00	0.00
Asset Turnover Full definition →		0.00	0.00	0.00	0.00
Operating CF/Net income Full definition →		0.74	0.23	1.59	0.76
Capex/Depreciation Full definition →		0.13	(31.02)	(0.06)	(0.18)
Research and Development Expense of Revenue Full definition →		187,813.33%	869,983.33%	1,830,200.00%	988,100.00%
Selling, General and Administrative Expense of Revenue Full definition →		71,246.67%	176,933.33%	477,750.00%	239,400.00%
Intangible Assets out of Total Assets Full definition →		0.00	0.00	0.00	0.00
Share Based Compensation of Revenue Full definition →		34,880.00%	426,150.00%	214,750.00%	113,300.00%
Graham Net Nets Full definition →		0.84	0.32	0.43	0.41
Graham Number Full definition →		0.00	0.00	0.00	0.00
Earnings Yield Full definition →		(141.75%)	(52.96%)	(68.79%)	(91.32%)
Free Cash Flow Yield Full definition →		(66.27%)	(36.44%)	(39.95%)	(53.27%)
Revenue per Share Full definition →		0.00	0.00	0.00	0.00
Operating CF per Share Full definition →		(1.56)	(1.89)	(1.76)	(1.45)
Capex per Share Full definition →		0.01	(2.43)	0.00	(0.01)
Free Cash Flow per Share Full definition →		(1.55)	(4.31)	(1.76)	(1.46)
Cash per Share Full definition →		17.50	14.46	11.61	8.74
Shareholders Equity per Share Full definition →		18.02	14.52	12.51	10.01
Interest Debt per Share Full definition →		0.00	0.00	0.00	0.00
Book value per Share Full definition →		18.02	14.52	12.51	10.01
Free Cash Flow Full definition →		(28.38)	(73.73)	(38.60)	(34.17)
Working Capital Full definition →		296.32	211.53	230.36	173.67
Capital Expenditures Full definition →		0.20	(41.47)	(0.09)	(0.25)
Net Current Asset Value Full definition →		249.36	169.09	190.34	136.20
EV/EBIT Full definition →		0.07	0.00	0.00	0.00
Capex to Sales Full definition →		(13.40)	6,912.50	44.50	62.75
Price to Operating Income Full definition →		0.00	0.00	0.00	0.00
Other line items
Average Payables Full definition →		3.08	4.13	4.60	3.63
Average Assets Full definition →		513.59	415.46	390.21	348.30
Average Common Equity Full definition →		429.91	315.51	305.09	266.37

Show all line items

Columns are period end dates

Stockrow Weekly